Secondary prevention of stroke is important: but all hypertensive drugs are not created equal?
- PMID: 15879334
- DOI: 10.1161/01.STR.0000166044.06026.46
Secondary prevention of stroke is important: but all hypertensive drugs are not created equal?
Comment on
-
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).Stroke. 2005 Jun;36(6):1218-26. doi: 10.1161/01.STR.0000166048.35740.a9. Epub 2005 May 5. Stroke. 2005. PMID: 15879332 Clinical Trial.
Similar articles
-
Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options.Drugs. 2007;67(7):955-63. doi: 10.2165/00003495-200767070-00001. Drugs. 2007. PMID: 17488141 Review.
-
Can large-scale trials or meta-analyses demonstrate blood pressure--independent effect of angiotensin receptor blockers?Hypertension. 2007 Oct;50(4):e73; author reply e74. doi: 10.1161/HYPERTENSIONAHA.107.097402. Epub 2007 Aug 27. Hypertension. 2007. PMID: 17724273 No abstract available.
-
Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.Expert Rev Cardiovasc Ther. 2009 May;7(5):459-64. doi: 10.1586/erc.09.3. Expert Rev Cardiovasc Ther. 2009. PMID: 19419253
-
[Utilizing progress in modern antihypertensive therapy. Treating hypertension effectively from the beginning].MMW Fortschr Med. 2005 May 12;147(19):48. MMW Fortschr Med. 2005. PMID: 15940938 German. No abstract available.
-
[Study on cognition and prognosis in the elderly].Nihon Rinsho. 2006 Aug;64 Suppl 6:425-30. Nihon Rinsho. 2006. PMID: 16981574 Review. Japanese. No abstract available.
Cited by
-
Clinical profile of eprosartan: a different angiotensin II receptor blocker.Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. doi: 10.2174/187152508785909500. Cardiovasc Hematol Agents Med Chem. 2008. PMID: 18855637 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical